Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis.

OBJECTIVE The purpose of this study was to determine whether routine hepatitis C virus screening in pregnancy is cost-effective. STUDY DESIGN A decision tree with Markov analysis was developed to compare 3 approaches to asymptomatic hepatitis C virus infection in low-risk pregnant women: (1) no hepatitis C virus screening, (2) hepatitis C virus screening and subsequent treatment for progressive disease, and (3) hepatitis C virus screening, subsequent treatment for progressive disease, and elective cesarean delivery to avert perinatal transmission. Lifetime costs and quality-adjusted life years were evaluated for mother and child. RESULTS In our base case, hepatitis C virus screening and subsequent treatment of progressive disease was dominated (more costly and less effective) by no screening, with an incremental cost of 108 US dollars and a decreased incremental effectiveness of 0.00011 quality-adjusted life years. When compared with no screening, the marginal cost and effectiveness of screening, treatment, and cesarean delivery was 117 US dollars and 0.00010 quality-adjusted life years, respectively, which yields a cost-effectiveness ratio of 1,170,000 US dollars per quality-adjusted life year. CONCLUSION The screening of asymptomatic pregnant women for hepatitis C virus infection is not cost-effective.

[1]  F. Ansaldi,et al.  Mother‐to‐infant transmission of hepatitis C virus: Rate of infection and assessment of viral load and IgM anti‐HCV as risk factors * , 2002, Journal of medical virology.

[2]  T. Kuroki,et al.  Mother-to-child transmission of hepatitis C virus. , 1991, The Journal of infectious diseases.

[3]  J. Hoofnagle,et al.  10‐year follow‐up after interferon‐α therapy for chronic hepatitis C , 1998 .

[4]  D. Gibb,et al.  Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission , 2000, The Lancet.

[5]  F. Parazzini.  Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial , 1999, The Lancet.

[6]  J. Delattre,et al.  Factors associated with serum alanine transaminase activity in healthy subjects: Consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C , 1998, Hepatology.

[7]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[8]  M. Koffler.  Epidemiology of hepatitis. , 1965, Lancet.

[9]  M. Alter,et al.  Epidemiology of Hepatitis C in the West , 1995, Seminars in liver disease.

[10]  H. Tilson,et al.  Economic impact of treatment of HIV-positive pregnant women and their newborns with zidovudine. Implications for HIV screening. , 1996, JAMA.

[11]  M. Shindo,et al.  Long‐term follow‐up study of sustained biochemical responders with interferon therapy , 2001, Hepatology.

[12]  R. Koretz,et al.  Non-A, Non-B Post-Transfusion Hepatitis: Looking Back in the Second Decade , 1993, Annals of Internal Medicine.

[13]  G. Davis,et al.  Prolonged treatment with interferon in patients with histologically mild chronic hepatitis C: a decision analysis , 1998, Journal of viral hepatitis.

[14]  N. Silverman,et al.  Hepatitis C virus in pregnancy: Seroprevalence and risk factors for infection , 1993, American journal of obstetrics and gynecology.

[15]  M. Hack,et al.  Neonatal and Pediatric Posttransfusion Hepatitis C: A Look Back and a Look Forward , 2000, Pediatrics.

[16]  S. Pauker,et al.  Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. , 1998, JAMA.

[17]  J. Saunders,et al.  Transmission of hepatitis C virus to infants of human immunodeficiency virus‐negative intravenous drug‐using mothers: rate of infection and assessment of risk factors for transmission , 1997, Journal of viral hepatitis.

[18]  T. Hoshika,et al.  Prospective reevaluation of risk factors in mother-to-child transmission of hepatitis C virus: high virus load, vaginal delivery, and negative anti-NS4 antibody. , 2000, The Journal of infectious diseases.

[19]  Cost-effectiveness of 24 or 48 weeks of interferon α-2b alone or with ribavirin as initial treatment of chronic hepatitis c , 2000 .

[20]  Joann E D’Esposito.  Bureau of Labor Statistics Web Site , 2000 .

[21]  J. Hoofnagle,et al.  Classification of chronic hepatitis: Diagnosis, grading and staging , 1994, Hepatology.

[22]  J. M. Calvo Romero,et al.  Gastric adenocarcinoma and kidney transplantation , 1998 .

[23]  H J Alter,et al.  Recovery, Persistence, and Sequelae in Hepatitis C Virus Infection: A Perspective on Long-Term Outcome , 2000, Seminars in liver disease.

[24]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[25]  F. Mannelli,et al.  Hepatitis C virus infection and related liver disease in children of mothers with antibodies to the virus. , 1997, The Journal of pediatrics.

[26]  M. Fernández-Bermejo,et al.  Chronic hepatitis C in children: A clinical and immunohistochemical comparative study with adult patients , 1998, Hepatology.

[27]  J B Wong,et al.  Estimates of the Cost-Effectiveness of a Single Course of Interferon-2b in Patients with Histologically Mild Chronic Hepatitis C , 1997, Annals of Internal Medicine.

[28]  M. Buti,et al.  Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C. , 2000, Journal of hepatology.

[29]  Milton C Weinstein,et al.  Empirically calibrated model of hepatitis C virus infection in the United States. , 2002, American journal of epidemiology.

[30]  J. Wong,et al.  Watchful Waiting with Periodic Liver Biopsy versus Immediate Empirical Therapy for Histologically Mild Chronic Hepatitis C: A Cost-Effectiveness Analysis , 2000, Annals of Internal Medicine.

[31]  M. Ruiz‐Moreno,et al.  Hepatitis C virus infection in children. , 1999, Journal of hepatology.

[32]  J. Pawlotsky,et al.  What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? , 1998, Hepatology.

[33]  J. Hess,et al.  Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. , 1999, Clinical pediatrics.

[34]  G. Zuin,et al.  Clinical features and progression of perinatally acquired hepatitis C virus infection , 2003, Journal of medical virology.

[35]  D. Gretch,et al.  Diagnostic Testing for Hepatitis C , 2000, Seminars in liver disease.

[36]  Joshua A. Salomon,et al.  Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. , 2003 .

[37]  M. Jonas.  Treatment of chronic hepatitis C in pediatric patients. , 1999, Clinics in liver disease.

[38]  Z. Younossi,et al.  Cost effectiveness of interferon α2b combined with ribavirin for the treatment of chronic hepatitis C , 1999, Hepatology.

[39]  F. Iber,et al.  Long-Term Mortality after Transfusion-Associated Non-A, Non-B Hepatitis , 1992 .

[40]  H. Blum,et al.  Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). , 1990, Journal of hepatology.

[41]  W. Grobman,et al.  The cost-effectiveness of voluntary intrapartum rapid human immunodeficiency virus testing for women without adequate prenatal care. , 1999, American journal of obstetrics and gynecology.

[42]  D. Rouse,et al.  The effectiveness and costs of elective cesarean delivery for fetal macrosomia diagnosed by ultrasound. , 1996, JAMA.

[43]  M. Alter,et al.  Epidemiology of Hepatitis C , 2018, Clinical liver disease.

[44]  P. Marcellin,et al.  Long-Term Histologic Improvement and Loss of Detectable Intrahepatic HCV RNA in Patients with Chronic Hepatitis C and Sustained Response to Interferon- Therapy , 1997, Annals of Internal Medicine.

[45]  D. Prati,et al.  Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women , 2000, Hepatology.

[46]  H. Souayah,et al.  Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. European Paediatric Hepatitis C Virus Network. , 2001, BJOG : an international journal of obstetrics and gynaecology.

[47]  B. Shneider,et al.  Hepatitis C in children. , 2000, New England Journal of Medicine.

[48]  Transmission of Hepatitis C Virus from Mothers to Infants , 1994 .

[49]  A. Peaceman,et al.  Maternal hospital charges associated with trial of labor versus elective repeat cesarean section. , 1998, Birth.

[50]  K. Ishak,et al.  Long‐term clinical and histopathological follow‐up of chronic posttransfusion hepatitis , 1991, Hepatology.

[51]  G. Foster,et al.  Effects of mode of delivery and infant feeding on the risk of mother‐to‐child transmission of hepatitis C virus , 2003, BJOG : an international journal of obstetrics and gynaecology.

[52]  Inda,et al.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. , 1999, The New England journal of medicine.

[53]  M. Sinha,et al.  Cost effectiveness analysis of different strategies of management of chronic hepatitis C infection in children. , 2000, The Pediatric infectious disease journal.

[54]  A. Alberti,et al.  Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. , 1992 .

[55]  O. Weiland,et al.  Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. , 2008, Liver.

[56]  S. Pauker,et al.  Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. , 2000 .

[57]  Terry Therneau,et al.  Cost-Effectiveness of 6 and 12 Months of Interferon- Therapy for Chronic Hepatitis C , 1997, Annals of Internal Medicine.

[58]  M. Alter,et al.  Epidemiology of Hepatitis C: Geographic Differences and Temporal Trends , 2000, Seminars in liver disease.

[59]  L. Klein,et al.  Routine human immunodeficiency virus infection screening in unregistered and registered inner‐city parturients , 1991, Obstetrics and gynecology.

[60]  M A Gerber,et al.  The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. , 1992, The New England journal of medicine.

[61]  Z. Younossi,et al.  Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. , 2001, The American journal of medicine.